Effect of smokeless tobacco (snus) on smoking and public health in Sweden

Objective: To review the evidence on the effects of moist smokeless tobacco (snus) on smoking and ill health in Sweden. Method: Narrative review of published papers and other data sources (for example, conference abstracts and internet based information) on snus use, use of other tobacco products, and changes in health status in Sweden. Results: Snus is manufactured and stored in a manner that causes it to deliver lower concentrations of some harmful chemicals than other tobacco products, although it can deliver high doses of nicotine. It is dependence forming, but does not appear to cause cancer or respiratory diseases. It may cause a slight increase in cardiovascular risks and is likely to be harmful to the unborn fetus, although these risks are lower than those caused by smoking. There has been a larger drop in male daily smoking (from 40% in 1976 to 15% in 2002) than female daily smoking (34% in 1976 to 20% in 2002) in Sweden, with a substantial proportion (around 30%) of male ex-smokers using snus when quitting smoking. Over the same time period, rates of lung cancer and myocardial infarction have dropped significantly faster among Swedish men than women and remain at low levels as compared with other developed countries with a long history of tobacco use. Conclusions: Snus availability in Sweden appears to have contributed to the unusually low rates of smoking among Swedish men by helping them transfer to a notably less harmful form of nicotine dependence.

[1]  G. Connolly,et al.  Five leading U.S. commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines. , 1995, Journal of the National Cancer Institute.

[2]  U. de Faire,et al.  Ambulatory 24-h blood pressure monitoring in healthy, middle-aged smokeless tobacco users, smokers, and nontobacco users. , 1998, American journal of hypertension.

[3]  L. Kozlowski,et al.  Some practical points on harm reduction: what to tell your lawmaker and what to tell your brother about Swedish snus , 2003, Tobacco control.

[4]  S. Shiffman,et al.  Tobacco harm reduction: conceptual structure and nomenclature for analysis and research. , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[5]  K Larsson,et al.  Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. , 2003, Respiratory medicine.

[6]  K. Fagerström,et al.  European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health , 2003, Tobacco control.

[7]  B. Ünal,et al.  Health effects associated with smokeless tobacco: a systematic review , 2003, Thorax.

[8]  U. de Faire,et al.  Long‐term use of smokeless tobacco and physical performance in middle‐aged men , 1997, European journal of clinical investigation.

[9]  B. Stegmayr,et al.  Smokeless Tobacco as a Possible Risk Factor for Stroke in Men: A Nested Case-Control Study , 2003, Stroke.

[10]  D. Hoffmann,et al.  Chemical profile of two types of oral snuff tobacco. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[11]  M. Jarvis,et al.  Nicotine intake and dependence in Swedish snuff takers , 2005, Psychopharmacology.

[12]  J. Lindell,et al.  Use of smokeless tobacco: blood pressure elevation and other health hazards found in a large‐scale population survey , 1992, Journal of internal medicine.

[13]  A. McNeill,et al.  Regulation of nicotine replacement therapies (NRT): a critique of current practice. , 2001, Addiction.

[14]  U. de Faire,et al.  Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. , 1994, American journal of public health.

[15]  M. Ernst,et al.  Behavioral and neural consequences of prenatal exposure to nicotine. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[16]  R. Nilsson.  A qualitative and quantitative risk assessment of snuff dipping. , 1998, Regulatory toxicology and pharmacology : RTP.

[17]  T. Blakely,et al.  Mortality among “never smokers” living with smokers: two cohort studies, 1981-4 and 1996-9 , 2004, BMJ : British Medical Journal.

[18]  K. Kendler,et al.  Society for Research on Nicotine and Tobacco. , 1996, Addiction.

[19]  Brian P. Flaherty,et al.  Most smokeless tobacco use is not a causal gateway to cigarettes: using order of product use to evaluate causation in a national US sample. , 2003, Addiction.

[20]  J. Henningfield,et al.  INDUSTRY WATCH Swedish Match Company , Swedish snus and public health : a harm reduction experiment in progress ? , 2001 .

[21]  K. Asplund,et al.  Tobacco and myocardial infarction: is snuff less dangerous than cigarettes? , 1992, BMJ.

[22]  J. Hirsch,et al.  Tobacco habits among teenagers in the city of Göteborg, Sweden, and possible association with dental caries. , 1991, Swedish dental journal.

[23]  P. Cole,et al.  Evolving patterns of tobacco use in northern Sweden , 2003, Journal of internal medicine.

[24]  R. West,et al.  A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler , 2000, Psychopharmacology.

[25]  S. O. Ibrahim,et al.  The Swedish snus and the Sudanese toombak: are they different? , 1998, Oral oncology.

[26]  C. Östenson,et al.  Cigarette smoking, oral moist snuff use and glucose intolerance , 2000, Journal of internal medicine.

[27]  U. de Faire,et al.  Smokeless tobacco use and atherosclerosis: an ultrasonographic investigation of carotid intima media thickness in healthy middle-aged men. , 1997, Atherosclerosis.

[28]  F. Dominici,et al.  Airborne particulate matter and mortality: timescale effects in four US cities. , 2003, American journal of epidemiology.

[29]  L. Alfredsson,et al.  Attack rate, mortality and case fatality for acute myocardial infarction in Sweden during 1987–95. Results from the National AMI Register in Sweden , 2000, Journal of internal medicine.

[30]  M. Galanti,et al.  Between harm and dangers. Oral snuff use, cigarette smoking and problem behaviours in a survey of Swedish male adolescents. , 2001, European journal of public health.

[31]  N. Benowitz.  Snuff, nicotine and cardiovascular disease: implications for tobacco control. , 1999, Journal of the American College of Cardiology.

[32]  G. Howard,et al.  Chronic disease mortality in a cohort of smokeless tobacco users. , 2002, American journal of epidemiology.

[33]  J. Henningfield,et al.  Pharmacokinetics and pharmacodynamics of moist snuff in humans , 1999, Tobacco Control.

[34]  H. Johansson,et al.  Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck , 1998, Cancer.

[35]  L. Hansson,et al.  Tobacco, alcohol and the risk of gastric cancer by sub‐site and histologic type , 1999, International journal of cancer.

[36]  M. Curvall,et al.  Mutagen levels in urine from snuff users, cigarette smokers and non tobacco users--a comparison. , 1987, Mutation research.

[37]  S. Syrjänen,et al.  Snuff use and smoking among senior high school students: effects of a snuff sales ban. , 2008, Oral diseases.

[38]  S. Slorach,et al.  Volatile N-nitrosamines in snuff and chewing tobacco on the Swedish market. , 1983, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[39]  R. Burnett,et al.  Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. , 2002, JAMA.

[40]  M. Eriksson,et al.  Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish case‐control study , 1998, International journal of cancer.

[41]  K. Asplund,et al.  Impact of smokeless tobacco use on smoking in northern Sweden , 2002, Journal of internal medicine.

[42]  G. Andersson,et al.  Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: a comparative study. , 1994, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[43]  H. Bartsch,et al.  Unusually high levels of carcinogenic tobacco-specific nitrosamines in Sudan snuff (toombak). , 1991, Carcinogenesis.

[44]  喬 嶋本.  Nested Case-control Study , 1992, Definitions.

[45]  James L. Repace,et al.  Indoor air pollution, tobacco smoke, and public health. , 1980, Science.

[46]  K. Asplund,et al.  Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men. , 1999, Journal of the American College of Cardiology.

[47]  R. Wallace,et al.  Clearing the smoke: assessing the science base for tobacco harm reduction. , 2001 .

[48]  M. Djordjevic,et al.  Effects of storage conditions on levels of tobacco-specific N-nitrosamines and N-nitrosamino acids in U.S. moist snuff , 1993 .

[49]  H. Bartsch,et al.  Tobacco-specific nitrosamines , 1996, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[50]  P. Paredi,et al.  [Real-time measurement of indoor particulate matter originating from environmental tobacco smoke: a pilot study]. , 2002, Epidemiologia e prevenzione.

[51]  K. Asplund,et al.  Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA Study. , 1995, Atherosclerosis.

[52]  M. Jarvis,et al.  Nasal nicotine solution: a potential aid to giving up smoking? , 1983, British medical journal.

[53]  J. Henningfield,et al.  Nicotine delivery kinetics and abuse liability. , 1993, Journal of consulting and clinical psychology.

[54]  R. Ferrence,et al.  Nicotine and Public Health , 2000 .

[55]  K. Asplund.  Smokeless tobacco and cardiovascular disease. , 2003, Progress in cardiovascular diseases.

[56]  A. Lindgren,et al.  The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia , 2000, International journal of cancer.